Peter Thompson
Director at Terremoto Biosciences.
Raised on Terremoto Biosciences filings
$40.7M
of $108.6M offered across 1 Form D filing
- Form D filings
- 1
- Teammates
- 6
- Last filing
- Apr 22, 2026
Company
Terremoto Biosciences
Biotech · South San Francisco, CA
Selective AKT1 inhibitors for breast cancer and solid tumors
Selective AKT1 inhibitors for breast cancer and solid tumors
- Investors
- 14
- Founded
- 2022
- Still open
- $67.9M
Terremoto Biosciences filings
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Apr 22, 2026 | Equity | $40.7M/ $108.6M | Form D |
- EquityFiled Apr 22, 2026Form D$40.7M/ $108.6M
